These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 24141294)
1. Clinical and hematological effects of hydroxyurea therapy in sickle cell patients: a single-center experience in Brazil. Silva-Pinto AC; Angulo IL; Brunetta DM; Neves FI; Bassi SC; Santis GC; Covas DT Sao Paulo Med J; 2013; 131(4):238-43. PubMed ID: 24141294 [TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148 [TBL] [Abstract][Full Text] [Related]
3. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy. Borba R; Lima CS; Grotto HZ J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630 [TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia. Keikhaei B; Yousefi H; Bahadoram M Glob J Health Sci; 2015 Aug; 8(3):252-6. PubMed ID: 26493428 [TBL] [Abstract][Full Text] [Related]
5. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Charache S Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197 [TBL] [Abstract][Full Text] [Related]
6. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia. Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591 [TBL] [Abstract][Full Text] [Related]
7. Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Green NS; Manwani D; Qureshi M; Ireland K; Sinha A; Smaldone AM Pediatr Blood Cancer; 2016 Dec; 63(12):2146-2153. PubMed ID: 27573582 [TBL] [Abstract][Full Text] [Related]
9. Cerebrovascular events in sickle cell-beta thalassemia treated with hydroxyurea: a single center prospective survey in adult Italians. Rigano P; Pecoraro A; Calvaruso G; Steinberg MH; Iannello S; Maggio A Am J Hematol; 2013 Nov; 88(11):E261-4. PubMed ID: 23828131 [TBL] [Abstract][Full Text] [Related]
10. Modulation of erythrocyte arginase activity in sickle cell disease patients during hydroxyurea therapy. Iyamu EW; Cecil R; Parkin L; Woods G; Ohene-Frempong K; Asakura T Br J Haematol; 2005 Nov; 131(3):389-94. PubMed ID: 16225659 [TBL] [Abstract][Full Text] [Related]
12. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia. Vicari P; Barretto de Mello A; Figueiredo MS Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590 [TBL] [Abstract][Full Text] [Related]
13. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease. Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586 [TBL] [Abstract][Full Text] [Related]
14. [Effect of hydroxyurea on hemoglobin S]. Torres AF; Eberle SE; Sciuccati G; Bonduel M Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083 [TBL] [Abstract][Full Text] [Related]
15. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922 [TBL] [Abstract][Full Text] [Related]
16. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Nevitt SJ; Jones AP; Howard J Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137 [TBL] [Abstract][Full Text] [Related]
17. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732 [TBL] [Abstract][Full Text] [Related]
18. Perception to hydroxyurea therapy in patients with sickle cell disease: Report from 3 centers. Korubo KI; Onodingene NM; Okoye HC; Omunakwe HE Ann Afr Med; 2021; 20(2):127-131. PubMed ID: 34213480 [TBL] [Abstract][Full Text] [Related]